2 assets in Lung Carcinoid Tumor

Therapeutic assets addressing Lung Carcinoid Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Edotreotide Lung Carcinoid Tumor	British Columbia Cancer Agency	P2	CCC (52)
212-lead pentixather Lung Carcinoid Tumor	Yusuf Menda	Early P1	C (39)